Julie Clark - Jun 1, 2021 Form 3 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role: Chief Medical Officer
Signature: Julie Clark, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol: ADVM
Transactions as of: Jun 1, 2021
Transactions value $: $0
Form type: 3
Date filed: 6/3/2021, 06:55 PM
Next filing: Aug 10, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ADVM	Common Stock						49.5K	Jun 1, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ADVM	Stock Option (Right to Buy)							Jun 1, 2021	Common Stock	60K	$18.10	Direct	F2
holding	ADVM	Stock Option (Right to Buy)							Jun 1, 2021	Common Stock	33.8K	$13.44	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 46,125 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) RSU upon the vesting thereof, subject to the following vesting schedules: (A) 5,625 of such RSUs vest as to 1/4 of the shares subject thereto on each annual anniversary of February 16, 2021 and (B) 40,500 of such RSUs vest as to 1/3 of the shares subject thereto on the six-month anniversary of March 31, 2021 (the "3/31/21 RSU Vesting Commencement Date"), and the remaining 2/3 of the shares subject thereto shall vest on the one-year anniversary of the 3/31/21 RSU Vesting Commencement Date, in each case, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F2	Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of May 15, 2020 (the "2020 Option Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the 2020 Option Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F3	Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 16, 2021 (the "2021 Option Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the 2021 Option Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.